Global Autism Drugs and Companies Pipeline Review H2 2016

Autism Treatment Pipeline Review H2 2016

PUNE, INDIA, August 30, 2016 / --
Autism - Pipeline Review, H2 2016’, provides an overview of the Autism pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Autism and features dormant and discontinued projects.

Complete report details @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @

- The report provides a snapshot of the global therapeutic landscape of Autism
- The report reviews pipeline therapeutics for Autism by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Autism therapeutics and enlists all their major and minor projects
- The report assesses Autism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Autism
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Autism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key points in table of content
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Autism Overview 10
Therapeutics Development 11
Pipeline Products for Autism - Overview 11
Pipeline Products for Autism - Comparative Analysis 12
Autism - Therapeutics under Development by Companies 13
Autism - Therapeutics under Investigation by Universities/Institutes 16
Autism - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Autism - Products under Development by Companies 21
Autism - Products under Investigation by Universities/Institutes 23
Autism - Companies Involved in Therapeutics Development 24
Addex Therapeutics Ltd 24
Aequus Pharmaceuticals Inc. 25
AgeneBio Inc. 26
APeT Holding BV 27
BioCrea GmbH 28
BrainStorm Cell Therapeutics Inc. 29
Cellceutix Corporation 30
Confluence Pharmaceuticals LLC 31
Coronis Partners Ltd. 32
Curemark, LLC 33
F. Hoffmann-La Roche Ltd. 34
GW Pharmaceuticals Plc 35
Heptares Therapeutics Limited 36
Intra-Cellular Therapies, Inc. 37
MedDay SA 38
Omeros Corporation 39
Otsuka Holdings Co., Ltd. 40
Retrophin Inc. 41
Saniona AB 42
Sumitomo Dainippon Pharma Co., Ltd. 43
Autism - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Target 46
Assessment by Mechanism of Action 49
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
(dextromethorphan + quinidine sulfate) - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
acamprosate calcium - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
ACT-01 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
ADX-71441 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
ADX-88178 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
aripiprazole - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
aripiprazole - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
carbetocin - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
CB-0306 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
CM-AT - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78

Buy this report @

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here